Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 216

1.
2.

Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy.

Motomura K, Natsume A, Fujii M, Ito M, Momota H, Wakabayashi T.

Leuk Lymphoma. 2011 Nov;52(11):2069-75. doi: 10.3109/10428194.2011.596967. Epub 2011 Jul 12.

PMID:
21745167
3.

High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.

Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M.

Lancet Oncol. 2010 Nov;11(11):1036-47. doi: 10.1016/S1470-2045(10)70229-1. Epub 2010 Oct 20.

PMID:
20970380
4.

[Therapeutic management of central nervous system lymphomas in a single hematological institute].

Iványi JL, Marton E, Plander M, Gyánó G, Czumbil L, Tóth C.

Orv Hetil. 2009 Oct 18;150(42):1937-44. doi: 10.1556/OH.2009.28703. Hungarian.

PMID:
19812012
5.

Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.

Dabaja BS, McLaughlin P, Ha CS, Pro B, Meyers CA, Seabrooke LF, Wilder RB, Kyritsis AP, Preti HA, Yung WK, Levin V, Cabanillas F, Cox JD.

Cancer. 2003 Sep 1;98(5):1021-8.

6.

Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).

Bergner N, Monsef I, Illerhaus G, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD009355. doi: 10.1002/14651858.CD009355.pub2. Review.

PMID:
23152274
7.

High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.

Holdhoff M, Ambady P, Abdelaziz A, Sarai G, Bonekamp D, Blakeley J, Grossman SA, Ye X.

Neurology. 2014 Jul 15;83(3):235-9. doi: 10.1212/WNL.0000000000000593. Epub 2014 Jun 13.

8.

Cognitive functions in primary CNS lymphoma after single or combined modality regimens.

Correa DD, Shi W, Abrey LE, Deangelis LM, Omuro AM, Deutsch MB, Thaler HT.

Neuro Oncol. 2012 Jan;14(1):101-8. doi: 10.1093/neuonc/nor186. Epub 2011 Oct 19.

9.

Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.

Ichikawa T, Kurozumi K, Michiue H, Ishida J, Maeda Y, Kondo E, Kawasaki A, Date I.

Clin Neurol Neurosurg. 2014 Dec;127:106-11. doi: 10.1016/j.clineuro.2014.10.011. Epub 2014 Oct 22.

PMID:
25459253
10.

Partial-brain radiotherapy for primary central nervous system lymphoma: multi-institutional experience.

Iwabuchi M, Shibamoto Y, Sugie C, Ayakawa S, Ogino H, Baba F.

J Radiat Res. 2016 Mar;57(2):164-8. doi: 10.1093/jrr/rrv085. Epub 2015 Dec 9.

11.

Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience.

Makino K, Nakamura H, Hide T, Kuroda J, Yano S, Kuratsu J.

Int J Clin Oncol. 2015 Feb;20(1):29-34. doi: 10.1007/s10147-014-0692-4. Epub 2014 Apr 11.

PMID:
24722885
12.

Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma.

Blasco H, Senecal D, Le Gouge A, Pinard E, Benz-de Bretagne I, Colombat P, Hulot JS, Chatelut E, Le Guellec C.

Br J Clin Pharmacol. 2010 Sep;70(3):367-75. doi: 10.1111/j.1365-2125.2010.03712.x.

13.

[Primary central nervous system lymphoma--a report of 32 cases with literature review].

Yi JQ, Lin TY, He YJ, Huang HQ, Xia ZJ, Xia YF, Xu RH, Guo Y, Guan ZZ.

Ai Zheng. 2006 Apr;25(4):476-80. Review. Chinese.

PMID:
16613684
14.

High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).

Schorb E, Finke J, Ferreri AJ, Ihorst G, Mikesch K, Kasenda B, Fritsch K, Fricker H, Burger E, Grishina O, Valk E, Zucca E, Illerhaus G.

BMC Cancer. 2016 Apr 21;16:282. doi: 10.1186/s12885-016-2311-4.

15.

Results of treatment of 112 cases of primary CNS lymphoma.

Yamanaka R, Morii K, Shinbo Y, Homma J, Sano M, Tsuchiya N, Yajima N, Tamura T, Hondoh H, Takahashi H, Kakuma T, Tanaka R.

Jpn J Clin Oncol. 2008 May;38(5):373-80. doi: 10.1093/jjco/hyn027. Epub 2008 Apr 15.

PMID:
18413337
16.

Advantages of dose-dense methotrexate protocol for primary central nervous system lymphoma: comparison of two different protocols at a single institution.

Aoki H, Ogura R, Tsukamoto Y, Okada M, Natsumeda M, Isogawa M, Yoshida S, Fujii Y.

Neurol Med Chir (Tokyo). 2013;53(11):797-804. Epub 2013 Oct 25.

17.

Phase II trial of temozolomide plus concurrent whole-brain radiation followed by TNV regimen as adjuvant therapy for patients with newly diagnosed primary CNS lymphoma.

Wang Y, Liu B, Xu D, Zhao H, Zhu Y, Xu J, Tao R.

Neurol India. 2013 May-Jun;61(3):260-4. doi: 10.4103/0028-3886.115065.

18.

High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.

Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, Frickhofen N, Feuerhake F, Volk B, Finke J.

J Clin Oncol. 2006 Aug 20;24(24):3865-70. Epub 2006 Jul 24.

PMID:
16864853
19.

Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy.

Watanabe T, Katayama Y, Yoshino A, Komine C, Yokoyama T, Fukushima T.

J Neurooncol. 2003 May;63(1):87-95.

PMID:
12814260
20.

Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.

Roth P, Martus P, Kiewe P, Möhle R, Klasen H, Rauch M, Röth A, Kaun S, Thiel E, Korfel A, Weller M.

Neurology. 2012 Aug 28;79(9):890-6. doi: 10.1212/WNL.0b013e318266fcb2. Epub 2012 Aug 15.

PMID:
22895585

Supplemental Content

Support Center